Ozempic vs Wegovy: Same Drug, Key Differences

You’ve probably heard both names tossed around like they’re rivals: Ozempic for diabetes, Wegovy for weight loss. Here’s the twist that surprises almost everyone — they’re the exact same drug. Same molecule, same manufacturer, same little once-a-week shot. So why do they have different names, different price tags, and wildly different reputations? Let’s clear it up.

This is educational information, not medical advice. Semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) are prescription-only medicines that must be prescribed and supervised by a licensed clinician. Versions sold online as “research use only” are not FDA-approved for human use. Never start, change, or stop a dose on your own, and never source or self-inject these drugs outside of legitimate medical care. Talk to your doctor or pharmacist first, especially if you take other medications or have a health condition.

Quick answer: Ozempic and Wegovy are both semaglutide, made by Novo Nordisk, given as a once-weekly injection under the skin. The difference is what they’re approved to treat and how high the dose goes. Ozempic is approved for type 2 diabetes (and to lower heart risk in people with diabetes), topping out at 2.0 mg per week. Wegovy is approved for chronic weight management and goes a notch higher, to 2.4 mg. Different label, different insurance coverage, identical active ingredient.

What is your main goal?

Lose weight Gain muscles Eat healthy Explore new cuisines

Powered by DietGenie

They’re literally the same molecule

This is the part worth repeating because so much confusion flows from missing it. Semaglutide is a GLP-1 receptor agonist — a drug that mimics a hormone your gut releases after you eat. It tells your brain you’re full, slows how fast your stomach empties, and helps your body manage blood sugar. If you want the bigger picture on how this whole class works, we covered it in our guide to GLP-1 medications for weight loss.

Ozempic and Wegovy both contain that same semaglutide. Both come as a prefilled pen you inject once a week, usually in the belly, thigh, or upper arm — the same general spots we walk through in where to inject a GLP-1. The pharmacology doesn’t change between them. What changes is the box, the approved use, and the maximum dose.

There’s also a pill version of semaglutide called Rybelsus, taken daily by mouth instead of injected. It’s a different format with its own quirks, and we break those down in our Rybelsus overview.

Suggested read: Mounjaro vs Zepbound: What's the Difference?

The real difference: approved use and dose

When Novo Nordisk first brought semaglutide to market, it was for type 2 diabetes, under the name Ozempic. It earned an FDA approval to help control blood sugar, and later an additional approval to reduce the risk of heart attack and stroke in adults with type 2 diabetes who already have cardiovascular disease. Its weekly dose climbs in steps to a maximum of 2.0 mg.

Then came the weight-loss data. Higher doses of the same drug produced striking results, so Novo Nordisk ran a dedicated obesity program and got semaglutide approved separately for chronic weight management — that’s Wegovy. It’s cleared for adults with a BMI of 30 or higher, or 27 or higher when paired with a weight-related condition like high blood pressure or type 2 diabetes. Wegovy also carries an approval to reduce cardiovascular risk in people with obesity or overweight who have established heart disease. Its top dose is a bit higher than Ozempic’s, at 2.4 mg per week.

So both share the same backbone, but they were studied, dosed, and labeled for different jobs. One was built around blood sugar. The other was built around body weight.

What about off-label use?

Here’s where it gets messy in real life. Because Ozempic and Wegovy are the same drug, a doctor can legally prescribe Ozempic “off-label” for weight loss — meaning for a purpose the FDA hasn’t officially signed off on for that specific brand. This happens a lot, partly because Wegovy spent long stretches in shortage and partly because insurance behaves differently for each.

That said, only Wegovy is FDA-approved for weight loss. Off-label prescribing is common and legal, but it’s a clinical judgment call your prescriber makes with you, not a loophole to chase on your own. The dosing schedules also differ slightly between the two pens, so following the titration plan your clinician sets matters. We get into the step-up logic in our semaglutide dosage guide.

Suggested read: Wegovy vs Zepbound: Which Wins for Weight Loss?

How much weight can you actually lose?

This is the headline most people care about, and the evidence behind Wegovy is genuinely strong. In the STEP 1 trial, adults with overweight or obesity (without diabetes) who took semaglutide 2.4 mg alongside lifestyle changes lost a mean of 14.9% of their body weight over 68 weeks, compared with about 2.4% in the placebo group.¹ For someone starting at 220 pounds, that’s roughly 33 pounds on average — and many people lost considerably more.

The catch worth being honest about: that result came at the 2.4 mg dose, which is Wegovy’s territory. Ozempic’s lower 2.0 mg ceiling can still drive meaningful weight loss, but the obesity-specific data was generated at the higher dose. So if weight is the whole goal, the dose matters, not just the molecule.

One quick reality check before you do the math in your head — average results aren’t promises, and the curve is different for everyone. Here’s a rough projection tool to play with:

It’s also worth knowing this isn’t only about the number on the scale. In the SELECT trial, semaglutide cut the risk of major cardiovascular events — heart attack, stroke, and cardiovascular death — by about 20% in people with obesity and existing heart disease, even those without diabetes.² That’s a big part of why the conversation around these drugs has shifted from “vanity” to genuine preventive medicine.

Suggested read: Saxenda (Liraglutide): How the Daily Shot Works

Side effects: identical, because it’s the same drug

Since Ozempic and Wegovy are the same semaglutide, the side effect profile is the same too. The most common complaints are gastrointestinal: nausea, vomiting, diarrhea, and constipation. These tend to be worst when you first start and each time you step up to a higher dose, then ease off as your body adjusts over the following weeks.³

The one practical wrinkle is dose. Because Wegovy climbs to 2.4 mg, some people notice a bit more nausea at the top of that ladder than they would on Ozempic’s 2.0 mg max. Slower titration and small, lower-fat meals usually help. We put together a fuller list of what to expect and how to manage it in our semaglutide side effects guide.

There are rarer but more serious risks to discuss with your doctor too — including pancreatitis, gallbladder issues, and a boxed warning about thyroid tumors seen in rodent studies. None of that should be self-managed, which loops back to the obvious: this is a supervised medication.

Cost and insurance: where they really diverge

If the drug is identical, why does it matter which name is on the box? Money, mostly. Insurers have historically been far more willing to cover semaglutide for diabetes (Ozempic) than for weight loss (Wegovy), because obesity coverage is patchy across plans. Some plans cover Wegovy with prior authorization, some exclude weight-loss drugs entirely, and out-of-pocket list prices for both run high without coverage.

This is why two people on the exact same molecule can have completely different experiences at the pharmacy counter. One has a diabetes diagnosis and a $25 copay; the other is paying hundreds a month for what’s chemically the same shot. It’s frustrating and not very logical, but it’s the system as it stands.

Is one “better” — and is there an alternative?

Neither is better in a vacuum. They’re the same drug pointed at different goals. If you have type 2 diabetes, Ozempic is the on-label, usually-better-covered choice. If weight management is the primary aim and you qualify, Wegovy is the one actually approved and dosed for that.

It’s also worth knowing semaglutide isn’t the only option. Tirzepatide (sold as Mounjaro for diabetes and Zepbound for weight loss) is a different molecule that acts on two gut hormones instead of one, and in head-to-head and trial data it has produced even larger average weight loss for many people. We compare the two directly in semaglutide vs tirzepatide if you want to weigh those tradeoffs.

Suggested read: Ozempic vs Mounjaro: How the Two Compare

Bottom line

Ozempic and Wegovy are the same semaglutide from the same maker, given the same way — once a week under the skin. The differences come down to label and dose: Ozempic for diabetes at up to 2.0 mg, Wegovy for weight management at up to 2.4 mg, with insurance often treating the two very differently. The right choice isn’t about which brand sounds trendier; it’s about your actual diagnosis, your goal, your coverage, and what your clinician recommends. Bring this comparison to that conversation, ask which indication fits you, and let the prescribing be a shared decision rather than a guess.